260 results on '"Brodovicz, Kimberly"'
Search Results
2. Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States
3. Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
4. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
5. Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry
6. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study
7. Patients With Stricturing or Penetrating Crohn's Disease Phenotypes Report High Disease Burden and Treatment Needs.
8. Sensitivity Analysis of Methods for Active Surveillance of Acute Myocardial Infarction Using Electronic Databases
9. Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes
10. Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S.
11. Patients With Stricturing or Penetrating Crohn’s Disease Phenotypes Report High Disease Burden and Treatment Needs
12. Environmental Carcinogens and Risk for Human Liver Cancer
13. Evidence-to-policy gap on hepatitis A vaccine adoption in 6 countries: Literature vs. policymakers’ beliefs
14. Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: The Hypoglycaemia In Portugal Observational Study–Emergency Room (HIPOS–ER)
15. Assessing the Impact of Propensity Score Estimation and Implementation on Covariate Balance and Confounding Control Within and Across Important Subgroups in Comparative Effectiveness Research
16. Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry.
17. Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database
18. Supplemental Material - Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry
19. Sulfonylurea Use and Risk of Hip Fractures Among Elderly Men and Women with Type 2 Diabetes
20. A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
21. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty ( EMPRISE ) study
22. Postprandial metabolic responses to mixed versus liquid meal tests in healthy men and men with type 2 diabetes
23. Exercise and Vitamin E Intake Are Independently Associated with Metabolic Abnormalities in Human Immunodeficiency Virus-Positive Subjects: A Cross-Sectional Study
24. Sa486 PATIENTS WITH PENETRATING AND/OR STRICTURING CROHN'S DISEASE HAVE A HIGHER REPORTED PREVALENCE OF ACTIVE INTESTINAL AND EXTRA-INTESTINAL SYMPTOMS, SURGERIES AND NEED FOR BIOLOGICS: ANALYSIS OF THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT WITH IBD
25. COMPARATIVE EFFECTIVENESS OF EMPAGLIFLOZIN IN REDUCING TOTAL CARDIOVASCULAR EVENTS IN THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
26. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
27. Confirming diagnoses of acute pancreatitis with commonly available electronic data
28. Glucagon-like Peptide 1–Based Drugs and Pancreatic Safety
29. Sulfonylurea Use Associated with Higher Emergency Room Utilization among Elderly Patients with Type 2 Diabetes: 976.
30. Additional file 1 of Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
31. Environmental Carcinogens and Risk for Human Liver Cancer
32. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. (Original Contribution)
33. Glycemic Response and Attainment of A1C Goals Following Newly Initiated Insulin Therapy for Type 2 Diabetes
34. Hepatitis B vaccination and the risk of multiple sclerosis
35. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design
36. Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure
37. 133-LB: Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study
38. 134-LB: Effectiveness and Safety of Empagliflozin in Routine Care Patients: Interim Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study
39. Incidence of lower extremity amputations among patients with type 1 and type 2 diabetes in the United States from 2010 to 2014
40. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
41. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
42. Predictive modeling of hypoglycemia for clinical decision support in evaluating outpatients with diabetes mellitus
43. Hypoadiponectinemia Is Associated with Insulin Resistance, Hypertriglyceridemia, and Fat Redistribution in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy
44. Economic Analysis of a Child Vaccination Project Among Asian Americans in Philadelphia, Pa
45. Cardiovascular safety of linagliptin compared with other oral glucose‐lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care
46. Predictive modeling of hypoglycemia for clinical decision support in evaluating outpatients with diabetes mellitus
47. 249-OR: Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
48. 16-OR: Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes
49. 1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
50. COMPARATIVE EFFECTIVENESS AND SAFETY OF EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.